Microvascular inflammation is
emerging as a significant challenge in kidney transplantation. This condition
significantly affects graft survival and requires a tailored approach to
patient care. Commonly linked to alloimmune responses, this condition can occur
without donor-specific antibodies, complicating both diagnosis and treatment. Given
the implications for patients with end-stage renal disease, understanding the
various phenotypes of microvascular inflammation and their impact on kidney
transplants is essential.
How Does Microvascular
Inflammation Impact Kidney Transplants?
This study analyzed over 16,000 kidney transplant
biopsies from 6,798 transplant recipients between 2004 and 2023, involving more
than 30 transplant centers worldwide. The biopsies were classified into two
newly defined categories:
- Microvascular inflammation without evidence of
antibody-mediated rejection;
- Probable antibody-mediated rejection.
The primary
assessment criteria included graft loss risk, the progression of transplant
glomerulopathy, and the presence of antibody-mediated rejection.
The findings indicate that microvascular
inflammation affects 4.8% of kidney transplant biopsies, presenting with
highly distinct phenotypes: 3.1% of cases without donor-specific antibodies and
1.7% with probable antibody-mediated rejection.
Additionally, patients with
microvascular inflammation—either without evidence of antibody-mediated
rejection or with probable antibody-mediated rejection— were found to have a
2.1 and 2.7 times higher risk, respectively, of graft loss compared to patients
without rejection. These patients also demonstrate an elevated risk of
developing transplant glomerulopathy.
Microvascular Inflammation in
Kidney Transplants: A Key Factor in Allograft Survival and Glomerulopathy
Progression
This study underscores the pivotal
role of microvascular inflammation in the survival of kidney transplants, highlighting
its impact on graft loss and glomerulopathy risk, even in the absence of
antibody-mediated rejection. A deeper understanding of these mechanisms is now
crucial for optimizing post-transplant care and fostering new therapeutic
strategies, which may also be beneficial for other types of organ transplants.
These advances also open promising avenues, such as the development of
treatments targeting innate immunity and T cells. Additionally, incorporating
new phenotypic clissifications allows for refined diagnostics and precise
treatment adjustments.
